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Summary One of the advantages of nanotechnology is the feasibility to construct therapeutic
particles carrying multiple therapeutics with defined structure and stoichiometry. The field of
RNA nanotechnology is emerging. However, controlled assembly of stable RNA nanoparticles
with multiple functionalities which retain their original role is challenging due to refolding
after fusion. Herein, we report the construction of thermodynamically stable X-shaped RNA
nanoparticles to carry four therapeutic RNA motifs by self-assembly of reengineered small
RNA fragments. We proved that each arm of the four helices in the X-motif can harbor one
siRNA, ribozyme, or aptamer without affecting the folding of the central pRNA-X core, and
each daughter RNA molecule within the nanoparticle folds into their respective authentic
structures and retains their biological and structural function independently. Gene silencing
effects were progressively enhanced as the number of the siRNA in each pRNA-X nanoparticles
gradually increased from one to two, three, and four. More importantly, systemic injection of
ligand-containing nanoparticles into the tail-vein of mice revealed that the RNA nanoparticles
remained intact and strongly bound to cancers without entering the liver, lung or any other
organs or tissues, while remaining in cancer tissue for more than 8 h.
© 2012 Elsevier Ltd.
∗ Corresponding author at: Department of Pharmaceutical Sci-
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Introduction
Living organisms possess wide assortments of elegant
nanomachines, patterned arrays and highly structured
macromolecules performing diverse biological functions.
Macromolecules of DNA, RNA and proteins have intrinsi-
cally defined features at the nanometer scale and can serve
as powerful building blocks for the bottom-up fabrication
1748-0132 © 2012 Elsevier Ltd.
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Figure 1 Sequence and secondary structure of phi29 DNA-packaging RNA (pRNA). (A) Illustration of the phi29 packaging motor
geared by hexameric pRNA ring (cyan, orange, green, blue, brown, and purple structures). (B) Sequence of pRNA monomer Ab′. The
central domain for constructing the pRNA-X is boxed. (C) The core of the pRNA-X domain composed of four RNA oligos (a, b, c, and
d). Helical segments are represented as H1, H2, H3 and H4. The additional bases used to construct the pRNA-X motif in helices H2
and H3 are marked in red. Ab′ indicates non-complementary loops [27].
of biomimetic nanostructures and nanodevices [1,2]. RNA
is a particularly attractive candidate for such applications
[3—8], since it can be designed and manipulated with a
level of simplicity characteristic of DNA, while possessing
a versatile flexibility in structure and function similar to
some properties of proteins [9]. Simple chemical modifica-
tions such as, 2′-Fluoro (2′F) can generate RNAs resistant
to degradation without changing its folding into appropri-
ate 3D structure, while retaining authentic biological and
enzymatic functions [10,11].
There are many types of RNA molecules that could
potentially be utilized for nanotechnology-based therapy
such as small interfering RNAs [12—14], ribozymes [15—17],
RNA aptamers [18,19], riboswitches [20,21], and miRNAs
[22—24]. Although the methods for gene silencing with high
efficacy and specificity have been achieved in vitro, the
effective delivery of RNA to specific cells in vivo remains
challenging. The development of a safe, efficient, specific
and nonpathogenic nanodevice for the delivery of multiple
therapeutic RNAs is in high demand. RNA nanotechnology
holds great potential in this regard: (1) Homogeneous RNA
nanoparticles can be manufactured with high reproducibil-
ity and known stoichiometry, thus avoiding unpredictable
side effects or nonspecific toxicity associated with hetero-
geneous structures. (2) Using the bottom up approach, RNA
nanoparticles can be assembled harboring multiple thera-
peutic, reporter and/or targeting payloads for synergetic
effects [12]. (3) Cell type-specific gene targeting can be
achieved via simultaneous delivery and detection modules
which reduces off-target toxicity and lowers the concentra-
tion of the drug administered, thus reducing the side effects
of the therapeutics. (4) RNA nanoparticle size typically
ranges from 10—50 nm, an optimal size for a non-viral vector
as they are large enough to be retained by the body yet small
enough to pass through the cell membrane via the cell sur-
face receptors mediated endocytosis. The advantageous size
has the potential to greatly improve the pharmacokinetics,
pharmacodynamics, biodistribution, and toxicology profiles
by avoiding non-specific cell penetration [25]. (5) Protein-
free RNA nanoparticles with RNA aptamers as anti-receptors
can yield superior specificity compared to protein anti-
receptors while displaying lower antibody-inducing activity.
This will provide an opportunity for repeated administration
and treatment of chronic diseases. (6) RNA nanoparticles are
treated as chemical drugs rather than biological entities,
which might facilitate FDA approval.
However, one of the challenges in this emerging
field of RNA nanotechnology is the relative instability
of the nanoparticles without covalent modifications or
cross-linking, resulting in the dissociation at ultra low
concentrations in vivo after systemic injection. This has
seriously hindered the delivery efficiency and therapeutic
applications of RNA nanoparticles.
The feasibility of RNA nanotechnology in disease therapy
has been exemplified in the phi29 pRNA therapeutic system
[11—15,17,26]. The DNA packaging motor of bacteriophage
phi29 (Fig. 1A) is geared by a hexameric pRNA ring [27—29],
which contains two functional domains [30,31]. The cen-
tral domain of each pRNA subunit contains two interlocking
loops, denoted as the right- and left-hand loops (Fig. 1B)
that can be reengineered to form dimers or trimers via hand-
in-hand interactions [32—36]. The helical DNA packaging
domain is located at the 5′/3′ paired ends [31,37]. The two
domains are connected by a three-way junction (3WJ) region
[11]. We have recently demonstrated that the 3WJ region
extracted from the pRNA can be assembled from three
pieces of RNA oligos to construct trivalent RNA nanoparti-
cles [11]. In this communication, we demonstrate that the
centerfold domain of the pRNA could be engineered to form
a X-shaped motif (Fig. 1C), which was thermodynamically
stable, resistant to denaturation by 8 M urea and remained
intact at ultra-low concentrations. Incubation of four RNA
oligos each carrying one of the four small RNA molecules,
siRNA, receptor binding aptamer, or folate resulted in the
formation of tetravalent RNA nanoparticles as potential
therapeutic agents. We proved that each one of the four
helices in the X-motif can serve as a sticky-end to link
one siRNA or other therapeutic molecules without affecting
the folding of the central pRNA-X core. Systemic injec-
tion of ligand-containing nanoparticles into the tail-vein
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of mice revealed that the RNA nanoparticles remained intact
and strongly bound to cancers without entering the liver,
lung or any other vital organs or tissues.
Results and discussion
Length and sequence requirements of the helical
stem regions of the pRNA for the assembly of the
X-motif
The pRNA-X motif was constructed by (1) opening the right-
hand loop of pRNA to insert 9 base pairs, thereby forming
a double helical segment (Helix H2), and (2) extending the
H3 helix by 4 base pairs (Fig. 1C). The length of the helices
H1, H3 and H4 were 8 base pairs, respectively, while H2
was 9 base pairs long. Although 6 base pairs are sufficient
for the assembly of the junction domain, 8 base pairs are
necessary to keep the junction domain stable under strongly
denaturing conditions [11].
Thermodynamically stable properties displayed by
the pRNA X-motif
The pRNA-X motif was assembled by mixing four RNA oli-
gos, denoted a, b, c, and d in stoichiometric ratio at room
temperature. The affinity and efficiency of assembly was
investigated by both gel shift assays and melting experi-
ments conducted under the physiological buffer TMS in the
presence of 5 mM magnesium and 100 mM sodium chloride at
pH 7.6. The gel-shift assays demonstrate that if one or two
strands are omitted (lanes 1—6), they have a faster migra-
tion rate compared to the pRNA-X-core (lane 7) (Fig. 2A,
top). The core remained stable in 8 M urea (Fig. 2A, bot-
tom), thereby demonstrating its stable properties. Melting
experiments displayed a very smooth, high-slope tempera-
ture dependent melting curve indicating that the four oligos
of the pRNA-X core (TM of 62.7 ± 3.2 ◦C) have a higher affin-
ity to interact favorably compared to any of the individual
component strands (Fig. 2B). The robust attributes of the
3WJ core have already been demonstrated using compe-
tition assays at different temperatures and in presence of
0—8 M urea [11].
Self-assembly of stable RNA nanoparticles
harboring small RNA molecules linked to the
X-motif
Extension of the phi29 pRNA at the 3′-end does not affect the
folding of pRNA global structure [11,34]. Accordingly, the
sequences of the four RNA oligos a, b, c, and d were placed
at the 3′-end of the pRNA monomer, Ab′. Mixing of the four
resulting pRNA chimeras at equimolar concentrations led to
the assembly of X-shaped branched nanoparticles harboring
one pRNA at each branch. AFM images confirmed the for-
mation of larger RNA complexes with four-branches (Fig. 3A
and B), which were consistent with gel shift assays com-
paring monomer (Ab′), dimer (Aa′), 3WJ-3pRNA [11] and
pRNA-X—4pRNA (Fig. 3C). The dimer (Aa′) formed via hand-
in hand interactions of interlocking loops is only stable up
to 2 M urea, while the 3WJ—3pRNA and the pRNA-X—4pRNA
Figure 2 Assembly and stability of the pRNA-X core. In the
table, ‘+’ indicates the presence of the RNA oligo in samples
of the corresponding lanes M: DNA ladder. (A) 15% native PAGE
and 8 M denaturing PAGE gels showing the step-wise assembly of
the pRNA-X core. (B) Melting curves for the individual pRNA-X
strands (magenta, red, blue, and black) and the pRNA-X core
(green).
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Figure 3 Construction of tetravalent pRNA-X nanoparticles harboring monomeric pRNA at each branch. (A) Schematic of pRNA-
X—4pRNA constructs, (B) corresponding AFM images, (C) 8% native (left) and denaturing (right) PAGE gel, (D) dissociation assay for
the pRNA-X—4pRNA constructs by 4-fold serial dilution with [32P] pRNA-X—4pRNA (lanes 1—9) from 100 nM to 1 pM. Arrow indicates
the lowest detectable concentration of 25 pM. Scale bar: 50 nm.
are both stable in presence of 8 M urea. The pRNA-X—4pRNA
nanoparticles can also be co-transcribed and self-assembled
in one step during transcription with high yield.
As a candidate therapeutic RNA nanoparticle, the pRNA-
X constructs with four branches harboring multi-module
functionalities have to remain intact after systemic deliv-
ery, where it will exist at ultra low concentrations due
to dilution by circulating blood. To assay the dissocia-
tion, [-32P] labeled pRNA-X nanoparticles were serially
diluted to extremely low concentrations (100 nM to 1 pM).
The concentration for dissociation was below the detec-
tion limit of the [32P]-labeling technology; at 25 pM in
TMS buffer, the lowest detectable concentration, the
pRNA-X nanoparticles showed no signs of dissociation
(Fig. 3D).
Construction of a variety of therapeutic RNA
nanoparticles using the X-motif as scaffold
Tetravalent RNA nanoparticles were constructed using
the pRNA-X motif as a scaffold by incorporating four
functional modules: MG (malachite green dye, triphenyl-
methane) aptamer, luciferase siRNA (siLuci), survivin
siRNA (siSurv) and folate (FA) (Fig. 4A), denoted
[pRNA-X/MG/FA/siLuci/siSurv] or corresponding scram-
ble siRNA control. The presence of the functional moieties
did not interfere with the formation of the pRNA-X core
and the tetravalent complex assembled with high affinity
(Fig. 4B). The purified constructs (lane 9, Fig. 4B) were
stable in absence of magnesium and remained intact
under strongly denaturing conditions, even after the
incorporation of functionalities. In the next sections, we
evaluated whether the incorporated RNA moieties in the
pRNA-X nanoparticles retain their original folding and
functionalities.
Assessment of MG fluorescence
MG binding aptamer [38] was used as model system for
structure and function verification. Free MG is not fluores-
cent by itself, but emits fluorescent light after binding to
the aptamer. Fused MG-binding aptamer retained its capac-
ity to bind MG, as revealed by its fluorescence emission
(Fig. 4C). The fluorescence is comparable to optimized pos-
itive controls and therefore confirming that the MG aptamer
assembled from two strands of the pRNA-X after incorpora-
tion into the RNA nanoparticles.
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Figure 4 Construction of multi-module RNA nanoparticles harboring MG (malachite green) aptamer, folate, luciferase siRNA, and
survivin siRNA. (A) Schematic and sequences of the tetravalent pRNA-X constructs. (B) Step-wise assembly of RNA nanoparticles
using the pRNA-X as scaffold with functionalities assayed by 8% denaturing urea PAGE. In the table, ‘+’ indicates the presence of the
RNA strands in samples of the corresponding lanes. (C) Functional assay of the MG aptamer incorporated in pRNA-X nanoparticles.
MG fluorescence was measured using excitation wavelengths 475 and 615-nm. (D) Target gene knock-down effects of survivin siRNA
showed by RT-PCR (GADPH is the endogenous control) on mRNA level and Western Blot assay (-actin bands served as loading
control) on protein level. (E) Dual-luciferase assay for target gene knock-down of luciferase gene. The relative firefly luciferase
activity reflects the level of luciferase gene expression and is obtained by normalizing firefly luciferase activity using the internal
control renilla luciferase activity. Error bars represent s.d. (N = 3).
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Figure 5 Binding and entry of tetravalent pRNA-X nanoparticles into targeted cells. (A) Flow cytometry revealed that [pRNA-
X/MG/FA/siLuci/si/Surv] nanoparticles bound and specifically entered cells. Positive and negative controls were Cy3—FA—DNA and
Cy3[pRNA-X/MG/NH2/siLuci/si/Surv] (without FA), respectively. (B) Confocal images showed targeting of folate receptor positive
(FA+) KB cancer cells by the co-localization (overlap, 4) of cytoplasm (green, 1) and fluorescent RNA nanoparticles (red, 2) (magnified,
right panel). Blue represents nuclei, 3.
Targeted gene silencing assay in cancer cell model
Two pRNA-X nanoparticles were constructed for assaying
the gene silencing effects harboring: (1) folate and survivin
siRNA [pRNA-X/MG/FA/siLuci/si/Surv]; (2) folate and sur-
vivin siRNA scramble control [pRNA-X/MG/FA/siLuci/siSurv
Scram]. After 48-h transfection, both reverse transcription-
PCR (RT-PCR) assayed on mRNA level and western blot
assayed on protein expression confirmed reduced survivin
gene expression level of [pRNA-X/MG/FA/siLuci/si/Surv]
nanoparticles compared to the scramble control (Fig. 4D).
The mechanism of siRNA release from the pRNA nanoparti-
cles is by Dicer processing, as established previously [14].
Targeted gene silencing of luciferase
Dual-luciferase reporter system was used to quantita-
tively measure the gene silencing effects of the pRNA-X
constructs harboring the siRNA targeting firefly luciferase
gene [39] (Fig. 4A). The relative luciferase activity was
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Figure 6 Construction of tetravalent pRNA-X nanoparticles
harboring multiple siRNA for enhanced gene silencing effects.
(A) Sequences and notations of siRNA used in tetravalent con-
structs. Blue: siLuci-1 and 1′; red: siLuci-2 and 2′; green: siLuci-3
and 3′; orange: siLuci-4 and 4′; black: control siRNA [42]. (B)
and (C) Quantification of Luciferase gene expression: Effects of
increasing number of different Luciferase siRNAs (siLuci-1, 2, 3
and 4) (A); and four identical siRNA constructs (siLuci-1, 2, 3 or
4) incorporated in the pRNA-X motif (B). RLU, relative luciferase
units; siLuci-1′, 2′ 3′ and 4′ represent reversed siRNA sequences
for siLuci-1, 2, 3 and 4, respectively. Error bars represent s.d.
(N = 3).
used to reflect the expression level of firefly luciferase
gene by normalizing the firefly luciferase activity with
the internal control, renilla luciferase activity. The results
indicated that [pRNA-X/MG/FA/siLuci/si/Surv] nanoparti-
cles displayed ∼70% decrease in firefly luciferase gene
expression (Fig. 4E).
Figure 7 Comparison of gene silencing effects for a single
vs. multiple siRNAs incorporated in the pRNA-X motif. (A—D)
Four identical siRNA (siLuci-1, A; siLuci-2, B; siLuci-3, C; siLuci-
4, D) compared with a single siRNA harbored at each pRNA-X
motif arm; RLU: relative luciferase units; siLuci-1′, 2′ 3′ and 4′
represent reversed siRNA sequences for siLuci-1, 2, 3 and 4,
respectively. Error bars represent s.d. (N = 3).
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Cell binding and entry of pRNA-X nanoparticles
Folate was incorporated in the pRNA-X nanoparticles to
serve as a cancer cell delivery agent via folate receptor-
mediated endocytosis [11,14,40]. Fluorescent pRNA-X
nanoparticles with folate conjugated into one of the
branches of the pRNA-X complex were tested for cell
binding efficiency. pRNA-X harboring FA and Cy3 labels
[Cy3—pRNA-X/MG/FA/siLuci/si/Surv] served as the test
sample, while the negative control harbored NH2 and Cy3
labels [Cy3—pRNA-X/MG/NH2/siLuci/si/Surv]. Flow cytom-
etry (Fig. 5A) and confocal imaging indicated a strong
binding of the RNA nanoparticles and efficient entry
into the targeted cells, as demonstrated by the excel-
lent co-localization and overlap of the fluorescent pRNA-X
nanoparticles (red) and cytoplasma (green) (Fig. 5B).
Gene silencing effects were progressively
enhanced as the number of siRNA in each pRNA-X
nanoparticles increased gradually from one, two
three to four
Tetravalent pRNA-X complexes were constructed harboring
multiple luciferase siRNAs to assay for enhanced gene silenc-
ing effects. Dual-luciferase reporter system was used to
quantitatively measure the gene silencing effects. For all
the constructs, the total concentration of RNA was kept con-
stant at 1.25 nM. The target sites on the luciferase gene for
the four siRNAs (Fig. 6A) were located at 153—173, 196—216,
498—518, and 846—869 positions, as published in the lit-
erature [41,42]. The incorporation of four identical siRNA
sequences compromised the assembly of the X-motif due to
self-folding of the complementary sequences of the respec-
tive siRNAs. To facilitate the assembly, the siRNA sequences
were reversed (denoted with a prime, such as siLuci-1′) at
alternate helical branch locations. The reversed sequences
had no impact on the functionality of the siRNA.
Silencing effects with increasing number of different
luciferase siRNA
As the number of different luciferase siRNAs were grad-
ually increased in the pRNA-X motif, progressive increase
in silencing effects were observed as follows, ∼25% (for
1 siRNA; 3 scramble siRNA), 57% (for 2 siRNA; 2 scramble
siRNA), 72% (for 3 siRNA; 1 scramble siRNA), and 81% (for 4
siRNA) (Fig. 6B).
Silencing effects of four identical luciferase siRNAs
Significant silencing effects were observed in presence of
four identical siRNAs fused to the pRNA-X motif, com-
pared to a single siRNA as follows, ∼74% (for four siLuci-1),
∼90% (for four siLuci-2), ∼80% (for four siLuci-3), and
∼72% (for four siLuci-4) (Fig. 6C). For comparison, we
constructed the X-motif harboring a single siRNA (either
siLuci-1 or 2 or 3 or 4) at helical locations H1, H2, H3
or H4, respectively (Fig. 7A—D). The silencing effects of
the four different siRNAs increased following the trend,
siLuci-2 > siLuci-1 ≈ siLuci-4 > siLuci-3. The functionality of
the siRNA was comparable at each of the arms of the X-
motif. The data demonstrated that greatly enhanced effects
were observed in presence of four identical siRNAs compared
to a single siRNA (Fig. 7A—D).
Figure 8 (A) and (B) siRNA and pRNA-X nanoparticles were
transfected into HT29 GFP-Luc cells with Lipofectamine 2000
(siRNA#1 and 2: 100 nM; pRNA-X: 1 nM). (C) Effect of pRNA trans-
fection on the cytotoxicity in HT29 cells. Growth inhibition was
measured after treatment of cells with pRNA for 24 h in 96-
well plates. Cell numbers were quantitated by staining with
sulforhodamine B and expressed relative to cells treated with
Lipofectamine alone. RLU, relative luciferase units. Error bars
represent s.d. (N = 3).
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Figure 9 In vivo binding and targeting of pRNA-X nanoparticles. (A) The pRNA-X (harboring Folate and Alexa-647) nanoparticles
specifically targeted folate-receptor positive tumor xenografts upon systemic administration in nude mice, as revealed by whole
body imaging (A), and internal organ imaging (B). Control: PBS treated mice. Scale bar: fluorescent intensity.
Silencing effects of pRNA-X harboring four luciferase
siRNAs versus single standard siRNA
Firefly luciferase reporter was chosen as knockdown tar-
get for in vitro pRNA-X treatment. Two siRNA sequences
(siLuci-1 and 2) were selected and tested in HT29 colon
cancer cells with stable luciferase expression. To demon-
strate that the pRNA-X system provides a superior delivery
vehicle for siRNA, a direct comparison of the in vitro knock-
down efficacy compared to standard siRNA (siLuciferase-1
and 2) was carried out (Fig. 8A and B). A 1% concentration of
pRNA-X nanoparticles with four siRNA modules can achieve
the same silencing effects (∼60—70% decrease compared to
scramble controls) as the siRNA by itself. Absence of nonspe-
cific luciferase inhibition was confirmed by sulforhodamine
B assay (Fig. 8C).
In vivo targeting of RNA nanoparticles to cancer
xenograft by systemic injection
To confirm the chemical and thermodynamic stability of the
X-shaped RNA nanoparticles for specific cancer targeting
in vivo, RNA nanoparticles were constructed with one of the
four RNA fragments carrying the folate to serve as a ligand
for binding to the cancer cells, and another RNA fragment
carrying the fluorescent dye Alexa-647. The nanoparticles
were systemically injected (i.e., tail vein injections) into
athymic nude mice bearing KB cells (folate receptor pos-
itive) xenografts in the subcutaneous flanks. Whole body
imaging (at time points, 1-h, 4-h and 8-h) were carried out
after intravenous administration of FA—pRNA-X—Alexa647
nanoparticles. The pRNA-X nanoparticles strongly bound to
the tumor xenografts within 4-h (Fig. 9). The animals were
sacrificed at 8-h time point and organ imaging revealed that
fluorescence was localized specifically in the tumor and was
not detected in other organs of the body, indicating that
the particles are not trapped in the liver, lungs, kidneys or
other tissues or organs after systemic injection (Fig. 9B). The
results were confirmed to be reproducible by three indepen-
dent labs with five trials. Together, these findings suggest a
very selective targeting of the pRNA nanoparticles to tumors
and not to normal tissues which would make this delivery
system highly efficacious for future clinical applications.
Conclusions
We demonstrated that the central domain of bacteriophage
phi29 motor pRNA can be engineered into a stable X-motif
to carry four functional modules in the absence of metal
ions. The resulting nanoparticles were thermodynamically
stable, and resistant to dissociation under strongly dena-
turing conditions or at ultra-low concentrations. Incubation
of four RNA oligos representing therapeutic functional
motifs resulted in the self-assembly of tetravalent RNA
nanoparticles as potential therapeutic agents. Progressive
enhancement of gene silencing effects were observed when
the number of siRNA in each pRNA-X nanoparticles increased
from one to two, three and four. The results demonstrated
that a wide range of therapeutic RNA molecules targeting
cancer and viral infected cells can potentially be fused to
the multivalent pRNA-X motif to achieve enhanced silencing
effects.
Experimental procedures
In vitro synthesis and purification of pRNA
The pRNA were synthesized by enzymatic methods as
described previously [31]. RNA oligos were synthesized
chemically by IDT (Iowa). RNAs were purified by 8 M urea
8% PAGE. The corresponding bands were excised under UV
shadow and eluted from the gel over 4 h at 37 ◦C in the
elution buffer (0.5 M NH4OAc, 0.1 mM EDTA, 0.1% SDS, and
0.5 mM MgCl2) followed by ethanol precipitation overnight
at −20 ◦C (2.5 volume of 100% ethanol and 1/10 volume of
3 M NaOAc). The precipitate was pelleted by centrifugation
(16500 × g, 30 min), washed with 70% ethanol, and dried by
speed vacuum. Finally, the RNA dried pellet was rehydrated
in 0.05% DEPC treated water and stored at −20 ◦C.
Construction of multi-module RNA nanoparticles
The sequences for each of the RNA strands a, b, c, and d
were added to the 3′-end of each 117-nt pRNA-Ab′ and syn-
thesized using two primers: 3′-end primer encoding the a, b,
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c, and d, respectively, and a common 5′-end primer and the
Ab′ template. The template was then used in transcription
mixture and the pRNA was then purified in 8% urea PAGE gel
in TBM buffer, as described previously [11].
The sequences for the luciferase siRNA, survivin siRNA,
malachite green (MG) binding aptamer and folate labeled
RNA were rationally designed with the sequences of the
strands a, b, c, and d, respectively (Fig. 4). Multi-module
nanoparticles pRNA-X/MG aptamer/Folate/luciferase siRNA
and survivin siRNA, denoted [pRNA-X/MG/FA/siLuci/siSurv]
or scramble control, denoted [pRNA-X/MG/FA/siLuci/siSurv
Scram] were assembled from five individual fragments
including a 26-nt folate labeled RNA (Trilink) or folate-DNA
strand (synthesized in house). The individual RNA strands
(fragments 1, 2, 3 and 4, Fig. 4A) were transcribed from DNA
template amplified by PCR. Fluorescent dyes were labeled
on one RNA strand by using the Label IT® siRNA Tracker Intra-
cellular Localization Kit, Cy3TM (Mirus Bio LLC). The five RNA
strands were mixed after purification in TMS buffer at equal
molar ratio and then heated up to 80 ◦C for 5 min, followed
by slow cooling to 4 ◦C. The assembled nanoparticles were
then purified from 8% native PAGE gel.
Dilution assay to test dissociation at extremely low
concentrations
The stability of the tetravalent pRNA-X—4pRNA nanopar-
ticles were evaluated by radiolabel assays. Purified [32P]
pRNA-X—4pRNA complexes were serially diluted from 100 nM
to 1 pM in TMS buffer, and then loaded onto 8% native PAGE
gel for autoradiograph.
Melting experiments
The melting experiments were conducted by monitoring
the fluorescence of the pRNA-X component strands using
the LightCycler® 480 Real-Time PCR System (Roche). 1×
SYBR Green I dye (Invitrogen) (emission 465—510 nm), which
binds double-stranded nucleic acids, but not single-stranded
ones was used for all the experiments. The respective RNA
oligonucleotides were mixed at room temperature in phys-
iological TMS buffer. The pRNA-X core strands were slowly
cooled from 95 ◦C to 20 ◦C at the ramping rate of 0.11 ◦C/s.
Data was analyzed by the LightCycler® 480 Software using
the first derivative of the melting profile. The TM value rep-
resents the mean and standard deviation from 4 independent
experiments.
Flow cytometry analysis of folate mediated cell
binding
Human cervical cancer Hela cells [American Type Culture
Collection (ATCC)] were maintained in folate-free RPMI-
1640 medium (Gibco), then trypsinized and rinsed with PBS
(137 mM NaCl, 2.7 mM KCl, 100 mM Na2HPO4, 2 mM KH2PO4,
pH 7.4). 200 nM Cy3 labeled pRNA-X complexes harboring
folate [Cy3—pRNA-X/MG/FA/siLuci/si/Surv], and folate-free
control [Cy3—pRNA-X/MG/NH2/siLuci/si/Surv] were each
incubated with 2 × 105 KB cells at 37 ◦C for 1 h. After wash-
ing with PBS, the cells were resuspended in PBS buffer. Flow
cytometry (Beckman Coulter) was used to observe the cell
binding efficacy of the Cy3—pRNA-X nanoparticles.
Confocal microscopy
Hela cells were grown on glass coverslides in folate free
medium overnight. Cy3 labeled pRNA-X complexes harboring
folate [Cy3—pRNA-X/MG/FA/siLuci/si/Surv], and folate-free
control [Cy3—pRNA-X/MG/NH2/siLuci/si/Surv] were each
incubated with the cells at 37 ◦C for 2 h. After washing
with PBS, the cells were fixed by 4% paraformaldehyde
and stained by Alexa Fluor® 488 phalloidin (Invitrogen) for
cytoskeleton and TO-PRO®-3 iodide (642/661) (Invitrogen)
for nucleus. The cells were then assayed for binding and cell
entry by Zeiss LSM 510 laser scanning confocal microscope.
Malachite green (MG) aptamer fluorescence assay
The pRNA-X tetravalent RNA nanoparticles [pRNA-
X/MG/FA/siLuci/si/Surv] harboring MG binding aptamer
(100 nM) [38] was mixed with MG (2 M) in binding buffer
containing 100 mM KCl, 5 mM MgCl2, and 10 mM HEPES (pH
7.4) and incubated at room temperature for 30 min (Fig. 4C).
The fluorescence was measured using a fluorospectrometer
(Horiba Jobin Yvon; SPEX Fluolog-3), excited at 475 nm
(scanning from 540 to 800 nm for emission) and 615 nm
(scanning from 625 to 800 nm for emission).
Assay for the silencing of genes in cancer cell
model
Two pRNA-X nanoparticles were constructed for assaying
the gene silencing effects harboring: (1) folate and survivin
siRNA [pRNA-X/MG/FA/siLuci/si/Surv]; (2) folate and Sur-
vivin siRNA scramble control [pRNA-X/MG/FA/siLuci/siSurv
Scram].
Hela cells were transfected with 25 nM of the individual
pRNA-X complexes using Lipofectamine 2000 (Invitrogen).
After 48-h treatment, cells were collected and target gene
silencing effects were assessed by both RT-PCR and Western
blot assays.
Cells were processed for total RNA using illustra RNAspin
Mini kits (GE Healthcare, Buckinghamshire, UK). The first
complementary DNA strand was synthesized on mRNA
(500 ng) from Hela cells using SuperScript III First-Strand
Synthesis System (Invitrogen) according to manufacturer’s
instruction. PCR was performed using GoTaq Flexi DNA
polymerase (Promega). Reactions were carried out in a
final volume of 25 L which contained complementary DNA
from first-strand synthesis (the cDNA template was 1:5,
1:25 and 1:50 diluted respectively), 1× GoTaq Flexi color-
less buffer, 2.5 mmol/L Mg2+, 0.2 mmol/L deoxynucleoside
triphosphates, 0.2 mol/L of each primer, and 0.02 U/L
GoTaq Flexi DNA polymerase. The PCR condition was 95 ◦C
for 5 min then 25 cycles of 94 ◦C for 1 min, 55 ◦C for 1 min
and 72 ◦C for 1 min, followed by 72 ◦C for 10 min.
Primers for human GAPDH [43] and survivin [44] are:
GAPDH left: 5′-ACGGATTTGGTCGTATTGGGCG-3′;
GAPDH right: 5′-CTCCTGAAGATGGTGATGGAA-3′;
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Survivin left: 5′-GCATGGGTGCCCCGACGTTG-3′;
Survivin right: 5′-GCTCCGGCCAGAGGCCTCAA-3′.
Cells were rinsed and harvested in lysis buffer. Pro-
tein concentrations were determined and equal amounts of
proteins were loaded onto a 15% PAGE. Membranes were
blocked, incubated with primary antibody to survivin and
-actin (R&D Systems, Minneapolis, MN), and conjugated to
a secondary antibody (Sigma—Aldrich, St. Louis, MO). Mem-
branes were then blotted by ECL kit (Millipore, Billerica, MA)
and exposed to film.
Assay for the silencing of genes in cancer cell
model
Dual-luciferase assays were used to test the potential
of the pRNA-X complex in escorting siRNA delivered into
cells. For dual-luciferase assays, Hela cells were seeded in
24-well plates. Gene silencing assays were performed by
co-transfecting [pRNA-X/MG/FA/siLuci/si/Surv] with both
plasmid pGL3 and pRL-TK (Promega, Madison, WI) coding for
firefly and renilla luciferase, respectively. The latter served
as an internal control to normalize the luciferase data (Dual-
Luciferase Reporter Assay System; Promega). Cells were
washed once with PBS and lysed with passive lysis buffer. The
plates were shaken for 15 min at room temperature. 20 L
of lysate were added to 100 L of luciferase assay reagent
(LAR II) and firefly luciferase activity was measured. Upon
addition of 100 L of Stop & Glo Reagent, control measure-
ments of renilla luciferase activity were then obtained. The
data was then normalized with respect to the renilla activity
for determining the average ratio of firefly to renilla activity
over several trials.
HT29 colon cancer cells, that express GFP and firefly
luciferase (HT29 GFP-Luc), were plated at 10,000 cells/well
in a 96-well black plate (Corning Life Sciences; Tewks-
bury, MA) overnight and then transfected with control
siRNA (NTC), siLuci#1, and siLuci#2 using Lipofectamine
(Invitrogen). The siRNAs and pRNA-X nanoparticles were
transfected into HT29 GFP-Luc cells at 100 nM and 1 nM
each, correspondingly. D-Luciferin potassium salt (Research
Products International Corp, Mount Prospect, IL) was dis-
solved in sterile PBS to make a stock solution of 10 mg/mL;
the cell culture media was removed before addition of
100 L of a 150 g/mL solution of D-luciferin in PBS.
Plates were incubated at 37 ◦C for 5 min before imaging.
The IVIS Spectrum system was used for in vitro imag-
ing of cells in 96-well plates. For quantification of the
detected light, regions of interest were drawn by using Liv-
ing Image 3.1 software, and the photon counts per second
from each well were recorded and plotted. Cell numbers
were quantified by staining with sulforhodamine B assay
(Geno Technology, St. Louis, MO) as described previously
[45].
AFM imaging
For all samples, specially modified mica surfaces (APS mica)
were used. The APS mica was obtained by incubation of
freshly cleaved mica in 167 nM 1-(3-aminopropyl)silatrane.
The details of APS mica surface modification is described
elsewhere [46,47]. The RNA samples were diluted with 1×
TMS buffer to a final concentration of 3—5 nM. Then, the
droplet of samples (5—10 L) was immediately deposited
on APS mica. After 2 min incubation on the surface, excess
samples were washed with DEPC treated water and dried
under a flow of Argon gas. AFM images in air were acquired
using MultiMode AFM NanoScope IV system (Veeco/Digital
Instruments, Santa Barbara, CA) operating in tapping mode.
Two types of AFM probes were used for tapping mode imag-
ing in air: (1) regular tapping Mode Silicon Probes (Olympus
from Asylum Research, Santa Barbara, CA) with a spring con-
stant of about 42 N/m and a resonant frequency between
300 and 320 kHz. (2) Non-contact NSG01 DLC probes (K-Tek
Nanotechnology, Wilsonville, OR) with a spring constant of
about 5.5 N/m and a resonance frequency between 120 and
150 kHz.
Animal trial: in vivo targeting of tumor xenograft
by systemic injection of pRNA-X nanoparticles
Male athymic nudenu/nu (6—8 weeks old) mice were obtained
from Taconic (Hudson, NY) and housed in clean, pathogen-
free rooms in an environment with controlled temperature
(27 ◦C), humidity, and a 12 h light/dark cycle. All animal
experiments were approved by the Institutional Animal Care
and Use Committee at University of Kentucky and were
conducted in accordance with guidelines issued by the
National Institutes of Health for the care of laboratory ani-
mals. Mice were fed a folate-free diet (Harlan Laboratories;
Indianapolis, IN) for a total of 2 weeks before the exper-
iment and injected with KB cells (3 × 106 cells per mouse
in 100 L PBS) subcutaneously. When the tumors grew to
about 500 mm3, the mice were anesthetized using isoflu-
rane gas (2% in oxygen at 0.6 L/min flow rate) and injected
intravenously through the tail vein with a single dose of
3 g of pRNA per gram of body weight of 2′-F U/C modified
Folate-Alexa647-labeled pRNA-X nanoparticle in 300 L of
PBS. Whole-body imaging (Ex-Max 650 nm/Em-Max 668 nm)
was carried out at 1-h, 4-h and 8-h after pRNA administration
on IVIS Spectrum station (Caliper Life Sciences; Hopkin-
ton, MA). Composite images obtained were comprised of
black and white digital photos with an overlay of images
reflecting fluorescent activity. The density map, measured
as photons/second/cm2/steradian (p/s/cm2/sr), were cre-
ated using the Living Image 3.1 (Caliper Life Sciences;
Hopkinton, MA) software and represented as a color gradient
centered at the maximal spot. Following CO2 asphyxiation
at 8-h after pRNA administration, the tumors, liver, heart,
lung and kidney of the mice were dissected and individually
imaged.
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